The Triglyceride/Glucose Index and SGLT-2 Inhibitors

NCT05915884 | Completed

• 1 other identifier: 1
• Study Type: observational
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

This study was designed to evaluate the change in triglyceride glucose index, one of the atherosclerotic markers, in patients with type 2 DM followed in the Internal Medicine Clinic of Samsun University, Samsun Training, and Research Hospital. Methods: The data of the patients who were followed up for at least 3 months by making a retrospective file review will be recorded and analyzed. It is planned to start the study following the ethics committee's approval.

Conditions

Metabolic Disease; Diabetes

Keywords

SGLT-2 inhibitor; triglyceride index

Outcome Measures

Primary Outcomes (1)

• Change in triglyceride index

  Decreased triglyceride index among patients using SGLT-2 inhibitors.

  3 months

Study Arms (1)

Type 2 diabetic patients using SGLT-2 inhibitors

The data of all patients who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria, the patients will be evaluated and the data of the patients admitted to the study will be analyzed. The triglyceride glucose index of the patients before starting the SGLT-2 treatment and the triglyceride glucose index at the end of 3 months of treatment will be calculated by the researchers using the data in the system. No additional blood tests or laboratory analyses will be performed on the patients.

Other: SGLT-2 inhibitors

Interventions

SGLT-2 inhibitors OTHER

This study is an observational study. It is not planned to do an interventional activity.

Type 2 diabetic patients using SGLT-2 inhibitors

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with a diagnosis of type 2 Diabetes Mellitus who applied to Samsun Training and Research Hospital Internal Medicine outpatient clinic for 12 months in 2022 and were started on SGLT-2 inhibitor will be examined. According to the inclusion and exclusion criteria stated above, the patients will be evaluated and the data of the patients admitted to the study will be analyzed.

You may qualify if:

• Type 2 DM
• Age \>18 years old
• Dapagliflozin 10 mg or empagliflozin 10 mg or 25 mg
• months follow-up period

You may not qualify if:

• Type 1 diabetes
• Gestational diabetes
• Age \< 18 years old
• Insufficient or missed laboratory test results
• Medical treatment for dyslipidemia
• Hypothyroidism

Sponsors & Collaborators

• Samsun Education and Research Hospital: lead

Study Sites (1)

Samsun Education and Research Hospital

Samsun, İlkadım, 55200, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Metabolic Diseases; Diabetes Mellitus

Interventions

Sodium-Glucose Transporter 2 Inhibitors

Condition Hierarchy (Ancestors)

Nutritional and Metabolic Diseases; Glucose Metabolism Disorders; Endocrine System Diseases

Intervention Hierarchy (Ancestors)

Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Hypoglycemic Agents; Physiological Effects of Drugs

Study Officials

• DÜRİYE SILA KARAGÖZ ÖZEN

  Samsun Education and Research Hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD,Internal Medicine Specialist

Study Record Dates

• First Submitted: June 14, 2023
• First Posted: June 23, 2023
• Study Start: June 10, 2023
• Primary Completion: October 28, 2023
• Study Completion: January 28, 2024
• Last Updated: April 26, 2024

Record last verified: 2024-04

Locations

TU (1)